Literature DB >> 29470854

The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.

David A Turner1, Rebekah Fong Soe Khioe1, Lee Shepstone1, Elizabeth Lenaghan1, Cyrus Cooper2, Neil Gittoes3, Nicholas C Harvey2, Richard Holland4, Amanda Howe1, Eugene McCloskey5, Terence W O'Neill6, David Torgerson7, Richard Fordham1.   

Abstract

The SCOOP study was a two-arm randomized controlled trial conducted in the UK in 12,483 eligible women aged 70 to 85 years. It compared a screening program using the FRAX® risk assessment tool in addition to bone mineral density (BMD) measures versus usual management. The SCOOP study found a reduction in the incidence of hip fractures in the screening arm, but there was no evidence of a reduction in the incidence of all osteoporosis-related fractures. To make decisions about whether to implement any screening program, we should also consider whether the program is likely to be a good use of health care resources, ie, is it cost-effective? The cost per gained quality adjusted life year of screening for fracture risk has not previously been demonstrated in an economic evaluation alongside a clinical trial. We conducted a "within trial" economic analysis alongside the SCOOP study from the perspective of a national health payer, the UK National Health Service (NHS). The main outcome measure in the economic analysis was the cost per quality adjusted life year (QALY) gained over a 5-year time period. We also estimated cost per osteoporosis-related fracture prevented and the cost per hip fracture prevented. The screening arm had an average incremental QALY gain of 0.0237 (95% confidence interval -0.0034 to 0.0508) for the 5-year follow-up. The incremental cost per QALY gained was £2772 compared with the control arm. Cost-effectiveness acceptability curves indicated a 93% probability of the intervention being cost-effective at values of a QALY greater than £20,000. The intervention arm prevented fractures at a cost of £4478 and £7694 per fracture for osteoporosis-related and hip fractures, respectively. The current study demonstrates that a systematic, community-based screening program of fracture risk in older women in the UK represents a highly cost-effective intervention.
© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  DXA; FRACTURE PREVENTION; HEALTH ECONOMICS; OSTEOPOROSIS; SCREENING

Mesh:

Year:  2018        PMID: 29470854      PMCID: PMC5993187          DOI: 10.1002/jbmr.3381

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

2.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 3.  A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.

Authors:  Mickaël Hiligsmann; Silvia M Evers; Wafa Ben Sedrine; John A Kanis; Bram Ramaekers; Jean-Yves Reginster; Stuart Silverman; Caroline E Wyers; Annelies Boonen
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

4.  Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Authors:  O Ström; F Borgström; S S Sen; S Boonen; P Haentjens; O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2007-02-28       Impact factor: 4.507

5.  At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.

Authors:  F Borgström; O Johnell; J A Kanis; B Jönsson; C Rehnberg
Journal:  Osteoporos Int       Date:  2006-07-18       Impact factor: 4.507

6.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

7.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

8.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

Authors:  Elisabeth Fenwick; Bernie J O'Brien; Andrew Briggs
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

9.  A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study.

Authors:  L Shepstone; R Fordham; E Lenaghan; I Harvey; C Cooper; N Gittoes; A Heawood; T J Peters; T O'Neill; D Torgerson; R Holland; A Howe; T Marshall; J A Kanis; E McCloskey
Journal:  Osteoporos Int       Date:  2012-10       Impact factor: 4.507

Review 10.  Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

Authors:  E Hernlund; A Svedbom; M Ivergård; J Compston; C Cooper; J Stenmark; E V McCloskey; B Jönsson; J A Kanis
Journal:  Arch Osteoporos       Date:  2013-10-11       Impact factor: 2.617

View more
  21 in total

1.  Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial.

Authors:  C M Parsons; N Harvey; L Shepstone; J A Kanis; E Lenaghan; S Clarke; R Fordham; N Gittoes; I Harvey; R Holland; N M Redmond; A Howe; T Marshall; T J Peters; D Torgerson; T W O'Neill; E McCloskey; C Cooper
Journal:  Osteoporos Int       Date:  2019-10-12       Impact factor: 4.507

2.  Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CT.

Authors:  Maria Pisu; David L Kopperdahl; Cora E Lewis; Kenneth G Saag; Tony M Keaveny
Journal:  J Bone Miner Res       Date:  2019-03-24       Impact factor: 6.741

3.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2018-10-15       Impact factor: 4.507

4.  Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study.

Authors:  C I Condurache; S Chiu; P Chotiyarnwong; H Johansson; L Shepstone; E Lenaghan; C Cooper; S Clarke; R F S Khioe; R Fordham; N Gittoes; I Harvey; N C Harvey; A Heawood; R Holland; A Howe; J A Kanis; T Marshall; T W O'Neill; T J Peters; N M Redmond; D Torgerson; D Turner; E McCloskey
Journal:  Osteoporos Int       Date:  2020-01-20       Impact factor: 4.507

Review 5.  A broader strategy for osteoporosis interventions.

Authors:  Ian R Reid
Journal:  Nat Rev Endocrinol       Date:  2020-03-17       Impact factor: 43.330

Review 6.  A brief history of FRAX.

Authors:  John A Kanis; Helena Johansson; Nicholas C Harvey; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2018-10-31       Impact factor: 2.617

Review 7.  Population-Based Osteoporosis Primary Prevention and Screening for Quality of Care in Osteoporosis, Current Osteoporosis Reports.

Authors:  William D Leslie; Carolyn J Crandall
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

8.  Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.

Authors:  E Söreskog; F Borgström; L Shepstone; S Clarke; C Cooper; I Harvey; N C Harvey; A Howe; H Johansson; T Marshall; T W O'Neill; T J Peters; N M Redmond; D Turner; R Holland; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2020-04-01       Impact factor: 4.507

Review 9.  Fracture prediction, imaging and screening in osteoporosis.

Authors:  Nicholas R Fuggle; Elizabeth M Curtis; Kate A Ward; Nicholas C Harvey; Elaine M Dennison; Cyrus Cooper
Journal:  Nat Rev Endocrinol       Date:  2019-09       Impact factor: 43.330

10.  Menopausal osteoporosis: screening, prevention and treatment.

Authors:  Eu-Leong Yong; Susan Logan
Journal:  Singapore Med J       Date:  2021-04       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.